- NGM Biopharmaceuticals (NASDAQ:NGM) +67% after aldafermin phase 2 results.
- More news on: NGM Biopharmaceuticals, Inc., NanoViricides, Inc., Enlivex Therapeutics Ltd., Stocks on the move, , Read more ...
Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
GARDEN CITY, N.Y., July 16, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 6.8% to $126.09 on volume of 414,790,976 shares Faraday Future Intelligent Electric Inc. (FFIE) fell 18.7% to $0.265 on volume of 162,165,405 shares Ginkgo Bioworks Holdings Inc. Class A (DNA) fell 12.6%...
A look at the top 10 most actives in the United States GlycoMimetics Inc. (GLYC) rose 42.5% to $0.38 on volume of 73,016,681 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.16 on volume of 71,818,174 shares Faraday Future Intelligent Electric Inc. (FFIE) fell 25.4% to $0.2431 on volume...